Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia
Jazz Pharmaceuticals will present 21 abstracts, including 11 late-breaking ones, at SLEEP 2026 in Baltimore. The data highlights the broad treatment effects of Xywav for narcolepsy and idiopathic hypersomnia, focusing on sleep inertia, quality of life, and cardiovascular safety.
Key figures
- Drug Name
- Xywav
- Abstract count
- 21
- Late breaking abstracts
- 11
- Sodium reduction percent
- 92
- Sodium content max dose mg
- 131
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.